Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
Sponsor: First Affiliated Hospital of Zhejiang University
Summary
Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome
Official title: A Multi-center Prospective Single Arm Clinical Study of Reduced Intensive 3 + 5 Idarubicin and Cytarabine Chemotherapy Plus Venetoclax as First-line Treatment for Adults With Acute Myeloid Leukaemia and High-risk Myelodysplastic Syndrome
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-04-02
Completion Date
2027-04-02
Last Updated
2024-03-05
Healthy Volunteers
No
Interventions
idarubicin
Idarubicin 6mg/m2 d5-7
Cytarabine
Cytarabine 60mg/m2 d5-9